2022 World Conference on Lung Cancer (ePosters)-EP16.04-024. HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer

EP16.04-024. HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer

Pdf Summary

A study conducted in China investigated the role of HMGB1 in promoting resistance to the drug gefitinib in non-small cell lung cancer (NSCLC). The study found that the expression of HMGB1 was higher in a gefitinib-resistant cell line compared to a sensitive one. Gefitinib treatment induced the expression of HMGB1 in both cell lines. Interfering with HMGB1 expression resulted in a down-regulation of the autophagy-related protein LC3II and an up-regulation of the protein P62, suggesting a link between HMGB1 expression and autophagy. In addition, interfering with HMGB1 expression in combination with gefitinib treatment inhibited cell proliferation and promoted apoptosis in the resistant cells, partially reversing their resistance. The overexpression of HMGB1, on the other hand, restored resistance to gefitinib in the sensitive cells. Animal experiments also confirmed that HMGB1 affected the sensitivity of the resistant cells to gefitinib. Overall, the study suggests that HMGB1 plays a role in the resistance of NSCLC cells to gefitinib through its regulation of autophagy. The findings provide new insights for overcoming drug resistance in NSCLC and may have implications for targeted therapies in clinical settings.

Asset Subtitle

Zhaoxia Wang

Meta Tag

Speaker Zhaoxia Wang

Topic Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

Keywords

China

HMGB1

gefitinib

non-small cell lung cancer

NSCLC

drug resistance

autophagy

cell proliferation

apoptosis

targeted therapies